Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study

GlobeNewswire April 4, 2023

Algernon (CSE:AGN) approved for SEC Tier II Regulation A+ US$10M offering

Trevor Abes  April 3, 2023

Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M

GlobeNewswire April 3, 2023

CSE Bulletin: New Listing - Algernon Pharmaceuticals Inc. 27APRIL2023 Rights

Newsfile March 27, 2023

Algernon (CSE:AGN) journeys toward revolutionary treatments with launch of rights offering

Research March 21, 2023

Algernon Pharmaceuticals Announces Launch of Rights Offering

GlobeNewswire March 21, 2023

Algernon (CSE:AGN) subsidiary appoints former NFL neurologist to advisory board

Trevor Abes  March 2, 2023

Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board

GlobeNewswire March 2, 2023

Algernon Pharmaceuticals (CSE:AGN) announces stock split

John Ballem  March 1, 2023

CSE Bulletin: Stock Split - Algernon Pharmaceuticals Inc. (AGN)

Newsfile March 1, 2023

Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split

GlobeNewswire February 28, 2023

Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor

GlobeNewswire February 21, 2023

Algernon Pharma (CSE:AGN) safe to proceed to next phase of DMT clinical study

Jonathon Brown February 16, 2023

Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase

GlobeNewswire February 16, 2023

Algernon Pharmaceuticals subsidiary Algernon NeuroScience doses first patient in stroke study

TheNewsWire January 17, 2023

Algernon Pharmaceuticals  (CSE:AGN) subsidiary doses first subject in Phase 1 DMT clinical stroke study

Brieanna McCutcheon  January 17, 2023

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

GlobeNewswire January 17, 2023

Algernon Pharmaceuticals (CSE:AGN) appoints Dr. Peter Dicpinigaitis to its Chronic Cough Advisory Board

John Ballem  January 11, 2023

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

GlobeNewswire January 11, 2023

Algernon Pharmaceuticals releases details of Phase 2b chronic cough study of Ifenprodil

TheNewsWire January 10, 2023